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ABSTRACT 
Background  Cockayne syndrome (CS) is a rare, autosomal recessive multi-system disorder 
characterised by pre- or post-natal growth failure, progressive neurological dysfunction, ocular 
and skeletal abnormalities and premature ageing. About half of the patients with symptoms 
diagnostic for CS show cutaneous photosensitivity and an abnormal cellular response to UV 
light due to mutations in either the ERCC8/CSA or ERCC6/CSB gene. Studies performed thus 
far have failed to delineate clear genotype-phenotype relationships. We have carried out a four-
centre clinical, molecular and cellular analysis of 124 patients with CS. 
Methods and Results, We assigned 39 patients to the ERCC8/CSA and 85 to the 
ERCC6/CSB genes. Most of the genetic variants were truncations. The mis-sense variants 
were distributed non-randomly with concentrations in relatively short regions of the 
respective proteins. Our analyses revealed several hotspots and founder mutations in 
ERCC6/CSB. Although no unequivocal genotype-phenotype relationships could be made, 
patients were more likely to have severe clinical features if the mutation was downstream of 
the PiggyBac insertion in intron 5 of ERCC6/CSB than if it was upstream. Also a higher 
proportion of severely affected patients was found with mutations in ERCC6/CSB than in 
ERCC8/CSA.  
Conclusion By identifying more than 70 novel homozygous or compound heterozygous 
genetic variants in 124 CS patients with different disease severity and ethnic backgrounds, we 
considerably broaden the CSA and CSB mutation spectrum responsible for CS. Besides 
providing information relevant for diagnosis of and genetic counselling for this devastating 
disorder, this study improves the definition of the puzzling genotype-phenotype relationships 
in CS patients. 
Key Words 
4 
 
ERCC6, ERCC8, CSA, CSB, Hotspot  
5 
 
INTRODUCTION 
Cockayne Syndrome (CS) (OMIM #216400 and #133540) is a rare autosomal recessive 
disorder characterised by severe developmental delay, mental retardation, microcephaly, 
cachexia and a variety of other features, which may include cataracts, retinal degeneration, 
sensorineural hearing loss, dental anomalies and photosensitivity [1-5]. There is a large 
variation in severity of the disorder, which has led to categorisation into three types: Type I is 
associated with normal features at birth, followed by the onset of clinical features starting in 
the first or second year of life. The clinical features are progressive, usually leading to death 
in the second or third decade of life. Type II represents a more severe form of the disorder 
with features present at birth or prenatally. This group typically does not survive beyond the 
first decade. Type III represents a group with less severe features than those in Type I. They 
may survive for several decades. Cerebro-oculo-facio-skeletal Syndrome (COFS) has also 
been used to describe a very severe form of the disorder. This categorisation is quite 
convenient for a rough description of the patients’ severity [2], but in reality there is probably 
a continuum of severity of features [6]. 
At the cellular level, a robust diagnostic test is provided by the response of RNA synthesis to 
UV irradiation of cultured fibroblasts [7]. Whereas RNA synthesis and subsequently DNA 
synthesis recover rapidly following UV-irradiation of normal fibroblasts, this recovery is 
much delayed or absent in CS fibroblasts [8]. Nearly all cases in which there is a clear 
clinical diagnosis of CS are defective in this test, and in almost all patients diagnosed by this 
test, the causative mutation lies in one of two genes, ERCC6/CSB (OMIM 609413) or 
ERCC8/CSA (OMIM 609412). The encoded proteins, CSB and CSA are respectively a DNA-
dependent ATPase [9,10] and a WD40 protein component of a large cullin4-mediated E3-
ubiquitin ligase complex [11,12]. The ATPase activity of the 1493-aa CSB protein falls into 
the SWI2/SNF family and is associated with seven so-called helicase domains, even though 
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CSB does not have helicase activity. Towards the C-terminus there is a ubiquitin-binding 
domain [13]. CSB can be modified by phosphorylation, ubiquitylation on lys991 [14] and 
SUMOylation, most likely on lys205 [15,16]. The 396 aa-CSA protein comprises a seven-
bladed WD40 propeller attached to the DDB1 protein via a helix-loop helix motif at the N-
terminus [12]. 
The best characterised role of the CS proteins is in the transcription-coupled branch of 
nucleotide excision repair (NER) of UV-induced DNA damage. This damage, when in the 
transcribed strand of active genes, results in stalling of RNA polymerase II. The CS proteins 
are thought to modify the chromatin in the region of the stalled polymerase, enabling the 
polymerase to back-track and then to assist in the recruitment of TFIIH and other proteins 
involved in subsequent steps of NER [17,18]. This role of the CS proteins readily explains 
the failure of RNA synthesis to recover following UV-irradiation of CS cells and the 
photosensitivity of the patients. However it is not so easy to reconcile with many of the other 
features of CS. Indeed a few patients, with so-called UV-Sensitive Syndrome (UVSS), have 
been identified with mutations in CSA, CSB  or a recently identified gene UVSSA [19-23]. 
Cells from these individuals show the same defective recovery of RNA synthesis as CS cells 
but the patients display only the sun-sensitivity and not the broad spectrum of other features 
of CS such as neurodegeneration and premature ageing [24]. These observations suggest that 
the CS proteins have other functions as well, and evidence has been provided for several 
other roles (reviewed in [5,25]), including the repair of oxidative damage in DNA [26-29] 
and roles in mitochondrial DNA metabolism [30-33]. A recent elegant study, using both 
whole brains and cultured cells, identified a crucial role for the CS proteins in expression of 
neuronal genes and thereby in neuronal differentiation [34]. Similar conclusions have been 
reached from a study in which iPSC-derived neuronal cells from CS patients had reduced 
7 
 
transcription of many neural-specific genes [35]. This role of CS proteins in neuronal 
differentiation could account for some of the developmental defects found in CS patients.  
In this manuscript, we have gained further insight into the genetics and molecular basis of CS 
by analysing the clinical features and mutations in 124 CS patients, combining data gathered 
over several decades from four Centres, in Strasbourg (France); Pavia (Italy); Nagasaki and 
Nagoya (Japan); and Brighton (UK). Our results have identified many novel genetic variants 
and provide insights into previously unreported genotype-phenotype relationships and their 
relevance for clinical diagnosis. 
MATERIALS AND METHODS 
Samples were obtained as skin biopsies, fibroblast cultures, blood or DNA extracted from 
blood, all with appropriate informed consent.  
Fibroblast cultures and lymphoblastoid cell lines were established from skin biopsies and 
blood lymphocytes respectively, and grown using standard procedures. In the Pavia, 
Nagasaki and Brighton labs, cells were first screened on a diagnostic basis using the post-UV 
recovery of RNA synthesis (RRS) test using liquid scintillation counting [7,36], 
autoradiography [37] or a fluorescence assay [7,36]. Several cell samples were also analysed 
for hypersensitivity to the killing effects of UV exposure and levels of UV-induced DNA 
repair synthesis (UDS). Only cells displaying a defective RRS were characterised further to 
identify the mutation in the defective CS gene. In Pavia, cell fusion with known CS-A or CS-
B cells using polyethylene glycol was used to establish complementation group [37]. In 
Japan, complementation group was established by transduction with lentivirus expressing 
either ERCC6/CSB or ERCC8/CSA cDNA [38]. Finally the appropriate gene was sequenced 
using genomic DNA (ERCC6 RefSeq NG_009442.1; ERCC8 RefSeq NG_009289.1) and/or 
cDNA (ERCC6 NM_000124.3; ERCC8 RefSeq NM_000082.3). In Strasbourg, RRS and 
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molecular screening (genomic and/or cDNA sequence) were performed concomitantly. 
Genomic sequencing was performed either by Sanger or next generation sequencing [39]. 
Mutation nomenclature follows the format indicated at http://varnomen.hgvs.org/. Nucleotide 
numbering of coding sequences starts with the A of the ATG translation initiation site as 
nucleotide 1. When appropriate, we consulted the Human Splicing Finder (HSF), a tool to 
predict the effects of mutations on splicing signals or to identify splicing motifs in any human 
sequence (http://www.umd.be/HSF3/HSF.shtml). 
Clinical examination was carried out by VL and colleagues for all patients analysed in 
Strasbourg. Descriptions of clinical features at the other centres were dependent on clinical 
notes supplied by the referring clinicians. 
RESULTS AND DISCUSSION 
Out of the 124 patients identified as having a specific defect in RRS, 39 were mutated in 
ERCC8/CSA (Table 1) and 85 in ERCC6/CSB (Table 2), representing 32 and 68% of the 
population respectively. Homozygous patients (30 CS-A and 43 CS-B) are listed first in order 
of mutation position. Compound heterozygotes (9 CS-A and 42 CS-B) are listed subsequently 
in order of the most 5’ of the two genetic variants. Tables 1 and 2 also summarise as much 
clinical data as we have available, including previous reports on 13 CS-A and 5 CS-B cases. 
 
CSA mutations 
We have identified 32 pathogenic genetic variants in CSA, of which 25 have not been 
reported previously. Six were mis-sense mutations, all but one previously unreported, and 
one a small in-frame indel. Mis-sense mutations are indicated below the CSA linear structure 
(Fig 1A) with the previously unreported alterations indicated in bold. CSA comprises a 
seven-bladed WD40 propeller attached to the DDB1 protein via a helix-loop helix motif at 
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the N-terminus [12]. All the newly identified mis-sense mutations affect residues that are 
conserved among CSA orthologs and are located in WD40 repeats. Together with previously 
reported mutations, indicated above the CSA linear structure, there is a particularly high 
concentration of mis-sense mutations around aa 200 (4 mutations within 12 aa) and aa 270 (3 
mutations within 7 aa). All the 13 mis-sense mutations are located in the blades of the beta 
propeller structure, with 8 of them clustered in blades 4 and 5 (Fig 1B), and are likely to 
disrupt the structure of the protein [12].  
All the mis-sense mutations are predicted to be pathogenic using Polyphen, MutPred2 and 
SIFT (Supplementary Table 1). We have confirmed their defective function by transducing a 
CS-A cell line, CS9LO, with virus containing the mutant cDNA (Figure 2A, B). Wild-type 
CSB almost completely restored RRS to the recipient UV-irradiated CS9LO cell line. In 
contrast, when the cells were transduced with any of the six mutant cDNAs, RRS remained 
close to the level of the untransduced cells (Figure 2A). The infection efficiency was similar 
for all transductions (Figure 2B). 
We have identified 19 protein-truncating genetic variants, of which 14 are new, that include 
frameshift, splicing and premature stop mutations. They are predicted to result in 18 distinct 
truncated proteins (12 new), because we found that the Thr134Leufs*13 truncation (due to 
exon 5 deletion, i.e. r.400_481del) is caused by two distinct mutations affecting either the 
splice acceptor site of intron 4 (c.400-2A>G in CS261ST) or the splice donor site of intron 5 
(c.479C>T in CS133NY). In addition, two mutations resulting in large in-frame deletions 
(p.Val282_Gln347del, Val282_Glu374del and p.Val27_Arg92del) are respectively predicted 
from c.966C>A and a previously unreported rearrangement involving part of intron 2 and 
exon 3, which results in a transcript lacking exons 2 and 3 (patient CS1LE). Interestingly, the 
genomic mutation c.966C>A (in exon 10), previously described as resulting in a single, full-
length normal-spliced transcript (r.966c>a, p.Tyr322*) [39], was shown to generate also two 
10 
 
abnormally spliced transcripts carrying the deletion of exons 10 and 11 (r.844_1122del; 
p.Val282_Glu374del in CS9IAF) and/or the deletion of exon 10 (r.844_1041del; 
p.Val282_Glu347del in CS5IAF and CS9IAF). Indeed, this mutation is predicted to alter an 
exonic splicing enhancer (ESE) site, and potentially alter the splicing as indicated by the 
bioinformatics tool HSF. 
Finally, at the genomic level we identified three new CSA genetic variants located in splice 
donor sites (c.481+1G>C, c.1041+1G>T and c.1122+1delG) most probably affecting 
splicing. The resulting transcripts could not be identified because of the unavailability of 
RNA samples. However, HSF analysis indicated potential splicing alterations for the three 
mutations as well as the activation of an intronic cryptic donor site for the latest two. 
 
CSB mutations 
In CSB, we identified 73 pathogenic genetic variants of which 46 were previously unreported. 
10 of the mutations were mis-sense, nine in-frame deletions (two small and seven large),  five 
null mutations leading to unexpressed transcripts and the rest being truncations resulting from 
stop (16), frameshifts (20) or splice mutations (13). The 10 mis-sense mutations are indicated 
in Fig 3A, below the CSB linear structure, with the 6 new mutations indicated in bold. Other 
previously reported mis-sense mutations are shown above the CSB linear structure.  
All mis-sense mutations are predicted to be pathogenic (Supplementary Table 1). We have 
confirmed the defective function of several of them by transducing a CS-B cell line, 
CS10LO, with virus containing the mutant cDNA (Figure 2C, D). Similar to the CSA data, 
wild-type CSB almost completely restored RRS to the recipient UV-irradiated CS10LO cell 
line, whereas with the six mutant cDNAs tested, RRS remained close to the level of the 
untransduced cells (Figure 2C). The infection efficiency was similar for all transductions 
(Figure 2D). 
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Table 1 Mutation and clinical data on CS-A patients 
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HOMOZYGOTES                      
CS15PV Morocco M 1.5 10 (14) I c.37G>T  r.(37g>u) p.(Glu13*) + - + + + + +  - -  + +  
CS2JE Israel 
(Ukraine) 
M 0.5 11 (13) I  r.37g>u p.Glu13* + - + + + +  OA       
CS218ST India M 0.7 13* I c.37G>T r.37g>u p.Glu13* + - + S P  -  - +  - + IV -  - [6] 
CS1LE UK 
(Pakistan
) 
F 0.3 9 I Rearrangement involving part 
of intron 2 and exon 3 
r.78_275del (exons 2-3)  p.Val27_Arg92del + - + M +    +      
CS30PV Italy F 0.2 0.8 I c.162delT  r.162delu p.Glu55Lysfs*13  + - - + + - - + + -   - [40] 
CS4PV Italy M 0.2 3 (6) II c.223_227del  r.223_227del  p.Asn75Glnfs*9 + + + S + C    +   +  
CS2NG Japan     c.[275+703_399+347del;399+
348_399+2007inv;399+2008_
399+2558delins8] (large 
deletion of exon 4 and 
inversion in intron 4) 
r.276_399 del (exon 4) p.Asp93Leufs*26               
CS3NG Japan                   
CS28NG Japan                   
CS29NG Japan                   
CS30NG Japan                   
CS37NG Japan                   
CS2OS Japan                  [41] 
CS2AW Japan                  [41] 
CS263ST France 
(Turkey) 
M 0.6 6 I c.316C>T r.(316c>u) p.(Gln106*) + - + S P - - + + - IV + -  
CS261ST Tunisia  F 0 11 I/II c.400-2A>G r.400_481del (exon 5)  p.Thr134Leufs*13 + + + S C C - + + - IV + -  
CS133NY USA M 2 (32*) 
 
I/III c.479C>T 
(third to last nt of exon 5) 
r.400_481del (exon 5)  p.Thr134Leufs*13 + - + + + +  + + +    [42] 
[43] 
CS1BR France F    c.481G>A r.[481g>a;481_482ins481+1_481+4 
(part of intron 5)] 
p.Val161Serfs*5 
 
              
CS165ST France 
(Turkey) 
M 0 2 II c.481+1G>C r.? p.? +   S P C -  + - IV  -  
CS24PV    5  c.598_600delinsAA  r.598_600delinsaa  p.Tyr200Lysfs*12               
CS1GLO 
(CS192ST) 
UK 
(Libya) 
M 0 7 I c.598_600delinsAA r.598_600delinsaa p.Tyr200Lysfs*12 + + +  +          
CS7PV Italy F 0.1 4 (9*) II c.719-1G>A  r.719_843del (exon 9)  p.Ala240Glyfs*8  + + + S + C    +     
CS276ST France M ? 15 III ? c.730C>T r.(730c>u) p.(His244Tyr) -  + S -  -  + + II +  [44] 
CS172ST France F 0 14* II c.752delT r.752delu p.Leu251Tyrfs*18 + - + S P C + + +  III + -  
CS260ST France M 0 28 III ? c.793A>C r.793a>c p.Thr265Pro +  + M +    + + II   [44] 
CS240ST India F 0 6 I/II c.802C>T r.(802c>u) p.(Arg268*) +  + + S C - - + + - V + -  
CS3BR UK M 0.5 2 (6*) II  r.812u>c  p.Leu271Pro + - + S + + - - - +  +   
CS9IAF Israel 
(Arab) 
F  3 I c.966C>A  r.[966c>a,844_1041del 
(exon10),844_1122del (exons 10-
11)] 
p.[Tyr322*,Val282_Gln347del,
Val282_Glu374del] 
+ - +  +          
12 
 
CS5IAF Israel 
(Arab) 
M 0.5 6 I c.966C>A r.[966c>a,844_1041del (exon10)] p.[Tyr322*,Val282_Gln347del] + - + +  +   - +  +   
GM02965 USA F 13 25 III  r.1049a>g  p.Tyr350Cys + - + mild    - +     [45] 
COMPOUND HETEROZYGOTES                         
CCS4 Japan F    c.[2T>A];[275+703_399+347d
el;399+348_399+2007inv;399
+2008_399+2558delins8 
(large deletion of exon 4 and 
inversion in intron 4)] 
r.[?];[(276_399 del (exon 4))] p.[?];[(Asp93Leufs*26)] + - + mild + - - - mild mild    [46] 
CS9LO UK F 1 2.5 I/II c.[282delT];[c.481G>A] r.[282delu];[481g>a;481_482ins48
1+1_481+4 (part of intron 5)] 
p.[Pro95Leufs*30];[Val161Serf
s*5] 
+ - + S + - - - + +  -   
CS11PV Italy M 2.5 7 (12*) I c.[300C>G];[c.399+10773_550
+837 (deletion spanning from 
intron 4 to intron 6)] 
r.[300C>G];[400_550del (exons 5-
6)]  
p.[Tyr100*];[Thr134Valfs*7]  + - + + + +  OA  +    [47] 
CS040ST France F 2 16* I c.[356C>T(;)618-1G>A] r.[(356c>u)(;)(618_626del)] p.[(Ser119Leu)(;)(Ala207_Ser2
09del] 
+  + M P - - + + + II +  - [44] 
CS6PV Italy F 0.8 5 (16*) I  r.[400_481del (exon 5]; 
[400_550del (exons 5-6)] 
p.[Thr134Leufs*13]; 
[Thr134Valfs*7] 
+ +  + + -  +  +     
CS16PV Italy F 0.2 8 (15) I c.[594_595insAT];[659C>G ] r.[594_595insau];[659c>g] p.[Asp199Metfs*14]; 
[Ser220*]  
+ + + + + - -  + +  + +  
CS309ST France M 0.25 2 I c.[611C>A];[1122+1delG] r.[(611c>a)];[?] p.[(Thr204Lys)];[?] + - + M + - - - - + III - - [44] 
CS1JE Israel 
(Tunisia/ 
Algeria) 
F  4.5 I c.[618-1G>A];[?]  r.[618_626del (first 9 nt of exon 
8)];[0]  
p.[Ala207_Ser209del];[0] + - + + +   +  +     
CS291ST France F 0.3 19* I c.[927delT];[1041+1G>T] r.[(927delu)];[?] p.[Phe309Leufs*19];[?] + - + S P C - - - + III + - [44] 
 
Details of 39 CS-A patients are summarised. Nucleotide numbering starts with the A of the ATG translation initiation site as nucleotide 1. Mis-sense and small 
in-frame deletion mutations are indicated in italics on shaded background. Mutation nomenclature follows the format indicated at http://varnomen.hgvs.org/. 
Protein alterations are deduced from the DNA changes. 
aM, moderate; S, severe. bC, congenital; P, progressive. cOA, Optic Atrophy. dPatients CS291ST, CS040ST, CS309ST, CS276ST, CS260ST correspond to 
cases 5, 6, 7, 8, 9 respectively in Ref 39 from NC and VL and we include them as new mutations in Fig 1.  
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Table 2 Mutation and clinical data on CS-B patients 
 
Code 
Country 
(origin) 
Sex 
A
ge
 a
t 
o
n
se
t,
 y
rs
 
A
ge
 a
t 
b
io
p
sy
 
(l
at
e
st
 r
e
p
o
rt
 o
r 
d
e
at
h
*)
, y
rs
 
C
lin
ic
al
 
cl
as
si
fi
ca
ti
o
n
 
Mutation  
genomic DNA 
Mutation  
cDNA 
Protein Alteration 
G
ro
w
th
 f
ai
lu
re
 
Lo
w
 b
ir
th
 w
e
ig
h
t 
C
ac
h
e
xi
a 
/ 
b
ir
d
-
lik
e
 f
ac
e
s 
M
e
n
ta
l 
re
ta
rd
at
io
n
a  
M
ic
ro
ce
p
h
al
yb
 
C
at
ar
ac
ts
b
 
M
ic
ro
p
h
th
al
m
ia
 
R
e
ti
n
al
 d
e-
ge
n
er
at
io
n
c  
D
e
af
n
e
ss
 
C
lin
ic
al
 p
h
o
to
-
se
n
si
ti
vi
ty
 
Fi
tz
p
at
ri
ck
 s
ki
n
 
ty
p
e
 s
ca
le
 
D
e
n
ta
l a
n
o
m
al
ie
s 
A
rt
h
o
gr
yp
o
si
s 
R
e
fe
re
n
ce
d
 
HOMOZYGOTES                      
CS18BR Germany M 3  I c.212delC r.212delc p.Leu72Cysfs*12 + - -   - - - - +     
CS3SH UK F  9  c.466C>T r.466c>u,423_543del (exon 3) p.Gln156*,Ser142Asnfs*4   +       +     
CS14LO UK F 6 23 I c.466C>T r.466c>u,423_543del (exon 3) p.Gln156*,Ser142Asnfs*4 +  + M +    + +  -   
CS27PV Italy M 1.2 6.5 I c.526C>T  r.526c>u,423_543del (exon 3) p.Arg176*,Ser142Asnfs*4 - - + + +  - - - +  - -   
CS010ST Lebanon 
(Iraq) 
F  5 I c.640G>T r.(640g>u) p.(Glu214*) + - + S P - -   + IV + -  
CS13PV Italy F 0.4 2.5 (6) I c.1070C>G r.1070c>g  p.Ser357*  + - + + +  + +  +  +   
CS201ST Iran M 0 3 II c.1128del r.(1128del) p.(Thr377Glnfs*28) + + + S P + -  + + III + -  
CS10LO UK (Africa) F 0.5 4 I c.1280dupT r.(1280dupu) p.(Ser429Lysfs*7) + - + + + -  - - +     
      PiggyBac insertion at c.1397+6912 (in intron 5)                
CS19PV Italy F 0 1.5 
(2.4*) 
II c.1431_1432delGA  r.1431_1432delga  p.Lys478Thrfs*9  + - + + + C + - - +  - -  
CS4TAN Turkey M   II c.1551G>A r.1551g>a p.Trp517* +  + + +     +     
CS8TAN Turkey F   II c.1551G>A r.1551g>a p.Trp517* +   + +     +     
CS35NG      c.1627C>T r.(1627c>u) p.(Ile543Phe)                
CS107ST Spain 
(India) 
F 0 2.5 II c.1690G>T r.(1690g>u) p.(Glu564*) + + + S P - - + +  IV + -   
CS253ST India M 0 3 II c.1936G>A r.(1936g>a) p.(Asp646Asn) +  + + S + -  +  - IV - -   
CS1OX UK F    c.1954C>T r.1954c>u p.Arg652*                
CS13MA Pakistan F 0  II c.1954C>T r.1954c>u p.Arg652* +  +  + +   +      
CS232ST France 
(Algeria) 
F 0 3 II c.1971_1974dup r.(1971_1974dup) p.(Thr659Cysfs*24) + + + S + C  - -  III +   
CS1PL UK M  34 III c.1993-5A>G r.1992_1993insauag p.Phe665Tyrfs*18 +  + -      -  -   
CS9TAN Turkey     c.2038A>G r.( 2038a>g) p.(Asn680Asp)               
CS1NE UK M    c.2047C>T r.2047c>u p.Arg683*     + +    +     
CS23PV Italy M 0.3 4 (6) I c.2143G>T  r.2143g>u  p.Gly715*  + - + + + + - + + -   +  
CS3BI UK    III c.2167C>T r.1993_2169del (exon 10) p.Phe665_Gln723del              [48] 
CS11MA UK F 0 1 II c.2167C>T r.1993_2169del (exon 10) p.Phe665_Gln723del + +  +  +         
CS22BR Brazil M     c.2203C>T r.2203c>u p.Arg735*                 
CS12RO (Italy) M  11  c.2203C>T r.2203c>u p.Arg735*               
CS17LO UK 
(Turkey) 
M  13 I  r.2203c>u  p.Arg735*  + - +  +          
CS128ST France 
(Bosnia) 
F 0.75 15 I c.2203C>T r.2203c>u p.Arg735* + - + M P - - - - + III + -  
CS7MA UK M 0 0.5 II c.2222_2230del r.2222_2230del p.Tyr741_Arg744delinsTrp + + + + + + +  +      
CS8PV Sri Lanka M 0.1 1 (4.5*) II c.2279_2280insA r.2279_2280insa p.Asn760Lysfs*2 +  + + + + +   +     
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CS144ST India  0 3.5 II c.2560C>T r.(2560c>u) p.(Gln854*) +  + S C - - +  + IV  +  
CS31PV Pakistan M 0 2 II c.2599-26A>G  r.2598_2599ins2599-25_2599-1 
(partial insertion of intron 13) 
p.Met867Thrfs*14  + + + + + + + - + -  + +  
CS20PV Senegal F 0 0.5 
(1.7*) 
II c.2624T>C  r.2624u>c  p.Leu875Pro + + + + + + +  -    +  
CS11LO UK M 0.5 0.5 II c.2830-2A>G r.2830_2924del (exon 16) p.Ala944Thrfs*10 + +  + + + +        
CS23BR UK (?) M 0 0.5 II c.2925-93_3778+527delinsTT r.2925_3778del (exon 17, 18) p.Gln976Trpfs*70      +   +      
CS210ST 
(CS4BL) 
UK M 0 1.5 II c.3052dupA r.(3052dupa) p.(Thr1018Asnfs*32) + + + S C C -  + -  + -  
CS241ST UK M    c.3536delA r.(3536dela) p.(Tyr1179Leufs*22) +  +       +     
CS25LO UK 
(Pakistan?) 
  4  c.3627_3628insT r.3627_3628insu p.Lys1210* + - + + +    +       
CS270ST Iran F  2  c.3862C>T r.(3862c>u) p.(Arg1288*) + - + S +   + + +     
CS071ST India M 0.3 10 I c.4063-1G>C r.(4062_4063ins4063-139_4063-
1;4063-1g>c (partial insertion of 
intron 20)) 
p.(Asp1355Valfs*32) + - + M P - - + - + V  -  
CS204ST India M  16 III + - + M       V + -  
CS221ST India M 4 13 III + + + M P - - + - + V + -  
CS222ST India F  8 I +  + S P   +   V    
CS27LO UK 
(Pakistan?) 
F 0 0.5  c.4180delA r.4180dela p.Arg1394Glufs*6 +   S + +         
COMPOUND HETEROZYGOTES                     
CS288ST France 
(Reunion) 
F 0 10 II c.[del exon1];[2047C>T] r.[?];[(2047c>u)] p.[?];[(Arg683*)] + + + S C P    + IV  - [44] 
CS195ST France F 0 4 II c.[(?_-176)_(422+1_?)del]; 
[1834C>T] 
r.[0];[1834c>u] p.[0];[Arg612*] + - + M + C  - - + + II    
CS1PR UK F 1 2  c.[466C>T];[2839C>T] r.[466c>u,423_543del (exon 
3)];[2839c>u] 
p.[Gln156*,Ser142Asnfs*4]; 
[Arg947*] 
+        -      
CS225ST 
(CS16LO) 
UK F 2 17 I/III c.[466C>T];[2599-26A>G] r.[466c>u,423_543del (exon 
3))];[(2598_2599ins2599-
25_2599-1 (partial insertion of 
intron 13))] 
p.[(Gln156*,Ser142Asnfs*4)]; 
[(Met867Thrfs*14)] 
+ - + M P P -  + + II + -  
CS5MA UK M 2    c.[466C>T];[2839C>T] r.[466c>u,23_543del (exon 
3)];[2839c>u] 
p.[Gln156*,Ser142Asnfs*4]; 
[Arg947*] 
+ - + +   +   +      
CS2LE UK F 33  III? c.[466C>T];[2203C>T] r.[466c>u,423_543del (exon 
3)];[2203c>u] 
p.[Gln156*,Ser142Asnfs*4]; 
[Arg735*] 
              
CS1SH UK F 4 14 I c.[466C>T]; [1412_1413delTG] r.[466c>u,423_543del (exon 
3)];[1412_1413delug] 
p.[Gln156*,Ser142Asnfs*4]; 
[Leu471Glnfs*16]  
+ -  - - -   - +     
CS1SO UK F 1.5 5 (14*) I c.[526C>T];[1954C>T] r.[526c>u,423_543del (exon 
3)];[1954c>u] 
p.[Arg176*,Ser142Asnfs*4]; 
[Arg652*] 
+ - + + + - - + + +     
CS1GO Sweden M 0.5 9 I c.[526C>T];[1765_1767delTGG] r.[526c>u,423_543del (exon 
3)];[1765_1767delugg] 
p.[Arg176*,Ser142Asnfs*4]; 
[Trp589del] 
+  + +  - - + + +     
CCS8 Japan  1  II c.[536_537insTA];[1834C>T] r.[(536_537insua)];[(1834c>u)] p.[(Asn180Ilefs*7)]; 
[(Arg612*)] 
              
CS289ST 
 
France M 2 13 I c.[543G>T];[543+4delA] r.[423_543del(exon 3)]; 
[423_543del(exon 3)] 
p.[Ser142Asnfs*4]; 
[Ser142Asnfs*4] 
+ - + M P - - - - + II + - [44] 
CS26PV Italy F 1 36 III c.[543+4delA];[2203C>T]  r.[423_543del (exon 3)];[2203>u] p.[Ser142Asnfs*4];[Arg735*] +  + + +  +  + +  + -  
CS250ST France F 0 2 II c.[818del];[1397+2T>A] r.[(818del)];[?] p.[(Lys273Serfs*56)];[?] + + + S + C  + + - II  -  
CS148ST South 
Africa 
M   I/II c.[935_936delinsG];[2167C>T] r.[?];[(1993_2169del(exon 10))]. p.[(?)];[(Phe665_Gln723del)] +   S       III    
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CS1WR UK M  1 (8*) II c.[1357C>T];[2286+1G>A] r.[1357c>u];[2286_2287ins2286 
+1_2286+96;2286+1g>a (partial 
insertion of intron 11)] 
p.[Arg453*];[Val763Ilefs*7] +  + +  +         
      PiggyBac insertion at c.1397+6912 (in intron 5)                
CS233ST France M 0 2* II c.[1518delG];[2923C>T] r.[(1518delg)];[2923c>u)] p.[(Lys506Asnfs*37)]; 
[(Arg975*)] 
+ + + S C C + -  + II + -  
CS058ST 
(CS2LI) 
UK F  10 I c.[1526+1G>T];[3952_3953delA
G]   
r.[1398_1684del (exons 6-7)]; 
[3952_3953delag] 
p.[Arg467_Arg562del]; 
[Arg1318Glyfs*12] 
+   M   -  + + I  -  
CS18NG Japan    II c.[1583G>A];[1834C>T] r.[(1583g>a)];[(1834c>u)] p.[(Gly528Glu)];[(Arg612*)]               
CS18PV Italy M 0 1.7 
(2.6*) 
II c.[1685+6T>G];deletion 
including exons 9 and 10 
r.[1527_1685del (exon 7)]; 
[1822_2169del (exons 9-10)] 
p.[Tyr510_Arg562del]; 
[Glu608_Gln723del] 
+ + + + + C +   -   -  
CS17PV Italy F 0.6 1.1 
(2.9*) 
I/II c.[1686-1G>A];[c.2827C>T] r.[1686_1821del (exon 
8)];[2827c>u,2826_2829del,2710_
2829del (exon 15)] 
p.[Phe563Argfs*3];[Gln943*,Gl
n943Profs*8,Asp904_Gln943d
el] 
+ - + + + C + + + -  - +  
CS25PV Italy M    c.[? (deletion including exon 
8)];[2203C>T] 
r.[1686_1821del (exon 
8)];[2203c>u]  
p.[Phe563Argfs*3];[Arg735*]                
CS10MA UK F 0.4 1.5  c.[1834C>T];[2167C>T] r.[0];[1993_2169del (exon 10)] p.[0];[Phe665_Gln723del] + +  + + - + - - +     
CS1LI UK M 0 1.5 II c.[1939G>A];[2167C>T] r.[0];[1993_2169del (exon 10)] p.[0];[Phe665_Gln723del] + - +  + +   + +     
CS18LO UK F 0 0.1 II c.[2008C>T];[2287-2A>G]  r.[2008c>u];[2287_2382del (exon 
12)]  
p.[Arg670Trp];[Val763_Gln794
del]  
+    + +    +     
CS32LO UK F    c.[2047C>T];[3862C>T] r.[2047c>u];[3862c>u] p.[Arg683*];[Arg1288*]   +            
CS12MA UK M 0  II c.[2047C>T];[2167C>T] r.[2047c>u];[1993_2169del (exon 
10)] 
p.[Arg683*];[Phe665_Gln723d
el] 
    + +   +      
CS1GGO Germany M   II c.[2060C>T];[2203C>T r.[2060c>u];[2203c>u] p.[Ser687Leu];[Arg735*] +         +     
CS278ST France M 0 3 II c.[2060C>T];[3862C>T] r.[(2060c>u)];[(3862c>u)] p.[(Ser687Leu)];[Arg1288*] + + + S + C + + - - II + - [44] 
CS3BL UK M 
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c. [2092_2093insG]; [2857C>A] r.[1993_2169del (exon 10)]; 
[2857c>a] 
p.[Phe665_Gln723del]; 
[Gln953Lys] 
          
 
   
CS22PV Italy M 0.5 3 (5) I c.[2096_2097insC];[2203C>T]  r.[2096_2097insc];[2203c>u]  p.[Leu700Valfs*60];[Arg735*] + + + + + - - OA - -  + -  
CS28PV Italy M 3 4.5 I c.[2096_2097insC];[2203C>T] r.[2096_2097insc];[2203c>u] p.[Leu700Valfs*60];[Arg735*]  + + + + -   -  +   -  
CS2BL 
 
UK F 0   c.[2143G>T];[2167C>T] r.[0)]; 
[1993_2169del (exon 10)] 
p.[0]; 
[Phe665_Gln723del] 
    + +         
CS26LO UK F    c.[2167C>T];[2092_2093insG] r.[1993_2169del (exon 10)]; 
[1993_2169del (exon 10)] 
p.[Phe665_Gln723del]; 
[Phe665_Gln723del] 
              
CS8MA UK M 0 1 II c.[2167C>T];[3661C>T] r.[1993_2169del (exon 
10)];[3661c>u] 
p.[Phe665_Gln723del];[Arg122
1*] 
+ + + + + +    +     
CS19LO UK M 0  II c.[2167C>T];[3259C>T] r.[1993_2169del (exon 
10)];[3259c>u] 
p.[Phe665_Gln723del];[Arg108
7*] 
+ -   + +         
CS19BR UK F 1  II c.[2167C>T];[2776G>C]  r.[(1993_2169del(exon 
10))];[(2776g>c)] 
p.[ Phe665_Gln723del];[(Ala92
6Pro)] 
+ + + + + +         
CS215ST UK M 0 0.6* II c.[2170-1G>A];[2599-26A>G] r.[(2170_2286del (exon 11))]; 
[(2598_2599ins2599-25_2599-1 
(partial insertion of intron 13))] 
p.[?];[(Met867Thrfs*14)] + + + S C C - + + +  
 
+ 
 
CS2GR Austria F 0 15 I c.[2203C>T];[3607_3608ins26] r.[2203c>u];[3607_3608ins26] p.[Arg735*];[Lys1203fs] + + + + + 
  
+ + 
 
 
   
CS14PV Italy M 1 3.5 (5)  I c.[2203C>T];[? (deletion of 
about 5.5Mb in 10q11.2)]  
r.[2203c>u];[0] p.[Arg735*];[0] + - + + + 
   
- +  - - 
 
CS21PV Italy F 1 21 (27) I c.[2551T>C];[3952_3953delAG]  r.[2551u>c];[3952_3953delag] p.[Trp851Arg]; 
[Arg1318Glyfs*12] 
+ + + + + 
   
+ -  + - 
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CS286ST France 
(Algeria) 
M 0 4 I/II c.[2599-26A>G];[4115delG] r.[(2598_2599ins2599-25_2599-1 
(partial insertion of intron 13))]; 
[(4115delg)] 
p.[(Met 867Thrfs*14)]; 
[(Gly1372Glufs*22)] 
+ - + M P C - - - - II - - [44] 
CS1BEL UK F 
 
7 (18*) 
 
c.[2830-2A>G];[3536delA] r.[2830_2924del (exon 
16)];[3536dela] 
p.[Ala944Thrfs*10]; 
[Tyr1179Leufs*22] 
+ 
       
+ +  
  
  
Details of 85 CS-B patients are summarised. Nucleotide numbering starts with the A of the ATG translation initiation site as nucleotide 1. Mis-sense and small 
in-frame deletion mutations are indicated in italics on shaded background. The position of the PiggyBac insertion is indicated. Mutation nomenclature follows 
the format indicated at http://varnomen.hgvs.org/. 
aM, moderate; S, severe. bC, congenital; P, progressive. cPatients CS288ST ,CS286ST, CS278ST, CS289ST correspond to cases 1, 2, 3 and 4, respectively in 
Ref 39 from NC and VL and we include them as new mutations in Fig 3. 
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The distribution of CSB truncation mutations is presented in Figure 3B (lower panel). Some 
general conclusions may be drawn from the present in-depth investigation together with 
previous studies (data up to 2010 reviewed by Laugel et al [39], and since 2011 listed in  
Supplementary Table 2).With two exceptions, all of the CSB mis-sense mutations are located 
either in or very close to the seven helicase domains, in particular in domains I and III (4 
mutations each) and domains IV-VI (9 mutations within 110 amino acids), emphasising the 
crucial role of these domains in CSB function. These helicase domains are involved in the 
DNA-dependent ATPase activity of the protein and confirm that this activity is vital for 
preventing the features of CS. The N- and C-terminal extensions are likely to be much more 
amenable to genetic variants that do not affect function, despite the demonstration that the C-
terminal part of the protein is essential for a normal cellular response to UV-irradiation 
[13,16]. This may imply that the structure of the C-terminal ubiquitin - binding domain needs 
to be intact, but the precise amino acid sequence is less crucial. Again, as might be 
anticipated, the truncation mutations are spread rather evenly across the protein (Fig 3B).  
Interestingly, the c.1834C>T and c.2143G>T result in p.Arg612* and p.Gly715*, 
respectively, and their transcript was detected only in homozygous or hemizygous patients. 
This transcript must be poorly expressed, presumably because of nonsense-mediated decay, 
because in compound heterozygotes only the transcript resulting from the second allele was 
detected.  
Furthermore, several genetic variants affect ERCC6/CSB splicing giving rise to either 
truncations or in-frame deletions. In particular, 10 mutations map at the canonical splice sites 
of different exons, 4 are located inside introns (c.1993-5A>G; c.2599-26A>G, c.1685+6T>G, 
c.543 + 4delA) and 3 inside exons (c.466C>T, c.526C>T and c.2092_2093insG). All the 
exonic-changes are likely to alter the splicing by creating novel exon-splicing enhancer (ESE 
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in the case of c.466C>T) or exon-splicing silencer (ESS for c.526C>T and c.2092_2093insG) 
sites according to HSF prediction. 
  
Recurring pathogenic genetic variants 
Mutations found in several patients are indicative of either founder effects or mutation 
hotspots. Although haplotype analysis would be required to distinguish definitively between 
these two alternatives, as a first approximation, we assume that if the pathogenic genetic 
variant is only found in a relatively limited geographical location, it is more likely to be a 
founder effect. In ERCC8/CSA, we found a complex rearrangement involving exon 4 in 8 
Japanese patients,  also previously reported in four Japanese patients by Ren et al [41], 
strongly indicating a founder mutation. Moreover, the c.966C>A mutation found in two 
patients of our cohort (CS9IAF, CS5IAF) was also previously described in 3 cases (CS2IAF, 
CS886VI/CS887VI) [39]. Since all the patients are of Arabic origin, albeit from different 
countries (Israel or Lebanon), this is also most likely a founder mutation. 
 
Nine CSB/ERCC6 pathogenic genetic variants occur in three or more patients (Table 3). The 
most common of these multiple occurrences are c.2203C>T,  c.2167C>T and c.466C>T 
respectively found in 12, 11 and 7 patients. Whereas c.2167C>T and c.466C>T are found 
almost exclusively in UK patients and may result from founder effects, c.2203C>T is found 
in individuals from several different countries and likely results from independent mutations. 
Interestingly, the C>T mutations in Table 3 that are more likely to result from a founder 
mutation are at CpA sites, whereas those more likely to result from independent mutations 
are at CpG sites. CpG sites are known to be mutational hotspots in the human genome [49].  
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Table 3 ERCC6/CSB mutations identified in three or more patients 
c.466C>T c.526C>T c.1834C>T c.1954C>T c.2047C>T c.2167C>T c.2203C>T c.2599-26A>G c.3862C>T c.4063-1G>C 
aaCag aaCga tgCag ttCga tcCga taCag taCga caAac acCga taGga 
CS3SH 
 
UK CS1SO UK CS10MA UK CS1OX UK CS1NE UK CS26LO UK CS22BR Brazil CS31PV Pakistan CS32LO UK CS071ST India 
CS1PR UK CS1GO Sweden CCS8 Japan CS13MA Pakistan CS32LO UK CS1LI UK CS12RO Italy CS215ST UK CS270ST Iran CS204ST India 
CS225ST UK CS27PV Italy CS18NG Japan CS1SO UK CS12MA UK CS8MA UK CS2LE UK-
Turkey 
CS225ST UK CS278ST France CS221ST India 
CS5MA UK   CS195ST France   CS288ST Reunion CS3BI UK CS1GGO Germany CS286ST France-
Algeria 
  CS222ST India 
CS14LO UK         CS11MA UK CS2GR Austria       
CS2LE UK         CS19LO UK CS14PV Italy       
CS1SH UK         CS10MA UK CS22PV Italy       
          CS12MA UK CS25PV Italy       
          CS148ST South 
Africa 
CS26PV Italy       
          CS19BR UK CS17LO UK-
Turkey 
      
          CS2BL UK CS128ST France-
Bosnia 
      
            CS28PV Italy       
 
For each mutation (top row), the sequence around the mutated base (CAPS) is indicated (second row), followed by the cell strain designations 
and country of origin of the patients’ families. No indication implies origin is unknown. 
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Relationship to clinical features 
No obvious genotype-phenotype correlation was identified in the CS-A patients reported in 
previous investigations (45 cases from 33 families). With the present study we have expanded 
the cohort of CS-A patients by describing 39 new cases, the majority of which are 
homozygotes. Focusing on the homozygous CS-A patients (33 from 24 families in the 
literature and 30 from 30 families in our cohort, excluding the 9 Japanese cases with a 
recurrent mutation), mis-sense mutations appear to be more frequently associated with mild 
phenotypes than protein-truncating mutations. The observation that the mis-sense alteration 
p.Trp361Cys, which interferes with transcription-coupled NER but not with the oxidative 
stress response, is associated with UVSS, a rare disorder characterized only by cutaneous 
photosensitivity [20], strongly supports the notion that the severity of the clinical features is 
related to the effects of the mutation on the additional roles of CSA outside transcription-
coupled NER, which include oxidative damage response, mitochondrial function 
maintenance and ribosomal DNA transcription. 
Previous analysis of mutations in CS-B patients (51 homozygous cases from 29 
families/kindreds and 37 compound heterozygotes from 32 families) have not identified any 
clear correlation between the site or the nature of the mutations with the type and severity of 
the clinical features  [50,51], although some more subtle relationships have been suggested. 
Several years ago, Tanaka and co-workers suggested  that CSB truncations generating no 
functional protein resulted in the mild phenotype of UVSS, whereas more C-terminal 
truncations might generate inactive protein that could interfere with other processes, thereby 
resulting in more severe phenotypes [19]. Weiner and colleagues showed that the human 
ERCC6/CSB gene contains a PiggyBac transposon insertion in intron 5 [52,53] (see Table 2 
and Figure 3). They showed that translation of ERCC6/CSB resulted in bona fide CSB 
protein, but also a CSB-PiggyBac fusion protein. Truncation mutations upstream of intron 5 
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would generate neither protein, whereas those downstream would generate only the CSB-
PiggyBac fusion, which was proposed to have deleterious effects [52]. We have analysed the 
severity of the clinical features in our patient cohort to see if they are in accord with these 
suggestions. In eight patients homozygous for truncations in the first 5 exons, six could be 
categorised as Type I, and one as Type II. No information is available for one patient. In 
contrast, in 28 patients homozygous for truncations downstream of exon 5, the numbers 
assigned to types I, II and III are 5, 12 and 3 respectively. There thus appears to be a tendency 
to more severe phenotypes (Type II) associated with downstream truncations, although this 
does not seem to be an absolute correlation. Patients with truncations upstream of the Piggy-
Bac insertion but severe clinical features have been reported previously (eg [54]). 
Furthermore, of the four patients homozygous for the mutation Asp1355Valfs*32, two were 
classified as type I and two as type III (see Table 2). Altogether these observations indicate 
that other factors, apart from the site of mutation, contribute to the severity of the 
pathological phenotype.  
 
In an earlier analysis, Laugel suggested that type II features were more prevalent in CS-B 
than in CS-A patients [6]. This is supported by our current data. The distributions for those 
patients for whom we have clinical data for Types I, II and III are 67, 21 and 12.5% for CS-A 
(21 patients) and 35, 56 and 10% for CS-B (60 patients). The individual clinical features for 
which we have information are summarised in Table 4, where they are also compared, where 
possible, with data from a recent analysis of 102 CS individuals by Wilson et al  [4]. Within 
our own cohort, there are few differences between CS-A and CS-B patients, with the possible 
exceptions of cataracts, low birth weight and microphthalmia, which are more prevalent in 
CS-B patients. The incidence of several features appears to be higher in our cohort than in 
that studied by Wilson et al (see Table 4).  Two possible explanations for this are: (1) they 
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could represent genuine differences between the two cohorts; (2) the analytical clinical 
criteria may differ between the two studies. Of the patients subjected to molecular analysis in 
[4] the ratio of CS-B to CS-A cases is very similar to that reported here. 
In a recent survey of CS patients in Japan, nearly all of them (41/47) were categorised 
clinically as Type I [3]. Unfortunately this survey did not include molecular analyses. 
However our data strongly suggest that there is a ERCC8/CSA founder mutation in Japanese 
CS patients. We may extrapolate this to suggest that many of the patients analysed in the 
survey by Kubota et al are likely also to have carried this founder mutation. As mentioned 
above, CS-A patients are more likely to fall into the Type I category. The features of the 41 
Japanese Type I patients are also included in Table 4. Deafness, photosensitivity and retinal 
 
Table 4 Summary of clinical features 
Clinical Feature CS-Aa CS-Ba Wilson et alb Kubota et ald 
Growth Failure 28/29 (97) 66/67 (99) 100 36/36 (100) 
Low birth weight 7/25 (28) 24/48 (50) 0  
Cachexia 26/27 (96) 55/56 (98)  38/39 (97) 
Mental retardation 27/27 (100) 55/57 (96)  41/41 (100) 
Microcephaly 26/27 (96) 55/57 (96) 100  
Cataracts 12/22 (54) 34/49 (69) 48 20/31 (65) 
Microphthalmia 2/16 (12.5) 13/33 (39)   
Retinal degeneration 10/18 (55) 16/30 (53) 43 25/28 (89) 
Deafness 15/21 (71) 26/43 (60) 44 28/31 (90) 
Photosensitivity 17/23 (74) 38/50 (76) 47 34/37 (92) 
Dental anomalies 11/14 (78) 17/25 (68) 46 18/25 (72) 
     
CSA/CSB mutations 39/39 (100) 85/85 (100) 39/40 (98)c  
 
The data present a summary from Tables 1 and 2. aNumber of cases with indicated feature/ 
total number for whom we have relevant information. % in parentheses; bData, expressed 
as %, from [4]; cMolecular analysis only available from 40 families – 39 were mutated in 
CSA or CSB, 1 was mutated in XPD. dData from [3]. 
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degeneration appear to be higher in the Japanese cohort. This may be partially explained by 
the average age of the Japanese patients (17.5 years), which appears to be significantly higher 
than in our cohort. Deafness and retinal degeneration are progressive and therefore more 
likely to occur in older patients. 
As also reported in earlier studies, clinical photosensitivity was found in the majority of our 
patients, even those with skin types IV and V on the Fitzpatrick scale (see Tables 1, 2 and 4). 
Nevertheless, as in other reports (eg [55]), we found no skin cancers in any of our patients. 
This may be explained by a recent finding that CS fibroblasts are not hypermutable by UV 
radiation [56]. 
In conclusion, our analyses show that the human mutation spectrum of the CS genes is not 
yet saturated, but mis-sense mutations are largely confined to a few relatively short regions. 
There are no definitive correlations between genotype and phenotype, but truncation 
mutations C-terminal to the PiggyBac insertion in ERCC6/CSB are more likely to confer a 
severe clinical phenotype than mutations N-terminal to this insertion or mutations in 
ERCC8/CSA. Our data will be important for diagnosis of and genetic counselling for this 
disorder. 
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FIGURE LEGENDS 
Figure 1 Mutation distribution in CSA 
(A) Distribution of mis-sense mutations across the CSA protein. Mutations identified in this 
study are indicated below the protein with new mutations indicated in bold. Other previously 
identified mis-sense mutations are indicated above the protein. 1-7 indicate the seven WD40 
domains of the CSA protein according to the reference sequence NP_000073.1. (B) Missense 
mutations associated with different CS phenotypes mapped onto the three-dimensional CSA 
protein structure (RCSB PDB, DOI: 10.2210/pdb4a11/pdb, [11 12]). Yellow, UVSS; 
Orange, CS type I; Violet, CS type II; dark Grey, CS type III. (C) Distribution of truncation 
mutations. Mutations have been grouped in intervals of 40 aa and columns represent the 
number of mutations for each group. The interval 0-40 includes mutations resulting in no 
transcript (asterisks). Black: new mutations identified in this study; grey: previously reported 
mutations also present in this study; white: other previously reported mutations. 
 
Figure 2 Lack of complementation with CSA and CSB mutations 
Wild type and various mutant ERCC8/CSA (A, B) or ERCC6/CSB (C, D) cDNAs were 
ectopically expressed by recombinant lentivirus infection in fibroblasts derived from a CS-A 
patient CS9LO or CS-B patient, CS10LO, respectively. (A, C) RRS activities were detected 
12 hours after UV irradiation (filled bars, 12 J/m2 UVC-irradiation; open bars, no-UV 
irradiation), and the value was normalised to activity measurement in non-irradiated cells. (B, 
D) Viral infection efficiency was confirmed by immunofluorescent staining of V5-tagged 
wild type and mutant CSA or CSB proteins, and calculated as the number of Alexa 488-
positive cells using a semi-automatic VTI system. w/o, without virus infection; w.t., wild 
type. Results from at least three independent experiments. Error bars indicate SD. 
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Figure 3 Mutation distribution in CSB 
(A) Distribution of mis-sense mutations across the CSB protein. Mutations identified in this 
study are indicated below the protein with new mutations indicated in bold. Other mis-sense 
mutations reported as pathogenic are indicated above the protein, with those now classified as 
polymorphic variants in parenthesis. Different domains of the protein are indicated: A, acidic 
domain; N, nuclear localisation domain; I, IA, II-VI, helicase-like domains; U, ubiquitin-
binding domain. (B) Distribution of truncation mutations. Mutations have been grouped in 
intervals of 100 aa and columns represent the number of mutations number for each group. 
The interval 0-100 includes mutations resulting in no transcript (asterisks). Black: new 
mutations identified in this study; grey: previously reported mutations also present in this 
study; white: other previously reported mutations.  
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